NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 362 filers reported holding NOVOCURE LTD in Q2 2021. The put-call ratio across all filers is 0.83 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $19,793 | +45.0% | 40,600 | -78.8% | 0.00% | -99.8% |
Q4 2022 | $13,648 | -99.9% | 191,651 | +8.5% | 1.39% | +60.5% |
Q3 2022 | $12,976,000 | -2.7% | 176,717 | +5.2% | 0.87% | +30.1% |
Q2 2022 | $13,337,000 | +4.0% | 167,976 | -0.6% | 0.67% | +24.2% |
Q1 2022 | $12,826,000 | +17.6% | 169,073 | +12.7% | 0.54% | +80.2% |
Q4 2021 | $10,905,000 | +41.3% | 150,000 | +10.7% | 0.30% | +18.7% |
Q3 2021 | $7,717,000 | +54.7% | 135,500 | +1.1% | 0.25% | +60.9% |
Q2 2021 | $4,988,000 | +2209.3% | 134,000 | +1340.9% | 0.16% | +1200.0% |
Q1 2021 | $216,000 | -78.9% | 9,300 | -43.6% | 0.01% | -58.6% |
Q4 2020 | $1,023,000 | +43.9% | 16,500 | -42.3% | 0.03% | -17.1% |
Q3 2020 | $711,000 | +442.7% | 28,600 | +31.8% | 0.04% | +400.0% |
Q4 2019 | $131,000 | -44.5% | 21,700 | -23.6% | 0.01% | -63.2% |
Q3 2019 | $236,000 | -58.4% | 28,400 | -8.4% | 0.02% | -47.2% |
Q3 2018 | $567,000 | +1475.0% | 31,000 | +93.8% | 0.04% | +1700.0% |
Q2 2018 | $36,000 | – | 16,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Invus Financial Advisors, LLC | 470,884 | $27,923,000 | 10.09% |
Darsana Capital Partners LP | 1,700,000 | $100,810,000 | 5.98% |
HARTLINE INVESTMENT CORP/ | 336,617 | $19,961,000 | 4.18% |
Rhenman & Partners Asset Management AB | 375,000 | $22,238,000 | 2.40% |
MORGAN JESS S & CO INC | 35,942 | $2,131,000 | 2.31% |
Soleus Capital Management, L.P. | 56,397 | $3,344,000 | 1.91% |
Bullseye Asset Management LLC | 45,161 | $2,678,000 | 1.43% |
Taylor Frigon Capital Management LLC | 46,304 | $2,746,000 | 1.36% |
COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $593,000 | 1.09% |
Redwood Investments, LLC | 192,986 | $11,444,000 | 1.01% |